Per the U.S. DoD, * Indicates a "small business" classification and ** indicates a "small disadvantaged business". NOTE: the U.S. DoD only publicly reports contracts valued at $6.5 million USD or greater. The contract language is EXACTLY as it appears on the official U.S. DoD website (http://www.defense.gov/contracts/) unless otherwise noted.
Principle Contractor: Novartis Vaccines and Diagnostics, Incorporated
Date Reported: 1/30/2012
Department: Defense Advanced Research Projects Agency
Contract Details: Novartis Vaccines and Diagnostics, Inc., Cambridge, Mass., is being awarded a $14,189,4020 technology investment agreement. The goal of this agreement is for Novartis to perform a research and development program designed to develop a self-replicating RNA vaccine platform. Work will be performed in Cambridge, Mass. Work is expected to be completed by November 2015. The Defense Advanced Research Projects Agency is the contracting activity (HR0011-12-3-0001).
Total Contract Value: $14,189,402
View More Contracts by Novartis Vaccines and Diagnostics, Incorporated